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Introduction 
In 1963, I published an article in Surgery, 
Gynecology, and Obstetrics describing the 
first cases of human liver transplantation. 
The following is a copy of the original 
summary: 
"A number of problems are described which 
must be surmounted for the clinical use of liver 
homotransplantation, based upon experience 
with 3 patients. The first patient died of 
hemorrhage during conclusion of the operation. 
The second and third patients lived for 22 and 
7 ~1 /2 days, respectively, both ultimately dying 
from multiple pulmonary emboli. Procurement 
of a viable and relatively undamaged donor 
organ [was] accomplished with the use of an 
extracorporeal circuit which perfuses and cools 
the [donor} liver immediately after death. It has 
been found necessary to decompress only the 
inferior vena cava during [the anhepaticJ time 
with an external bypass from the inferior to the 
superior vena caval systems. During operation, 
a bleeding diathesis was regularly detectable. 
The use of the external bypass and [delayed] 
hypercoagulability may have contributed to the 
formation of the [pulmonary] emboli. Hepatic 
functions were immediately deranged [post~ 
operatively], probably as the result of injury 
incurred during the transplantation, with 
progressive improvement thereafter. Bioche~ 
mical evidence of [irreversible] homograft 
rejection was not observed, and at autopsy in 
the last 2 patients there was surprisingly good 
gross and histologic preservation of graft 
structure. Therapy with azathioprine, pred~ 
nisone, and actinomycin C had forestalled the 
rejection process." (1) 
These 3 attempts at human liver repla~ 
cement followed 7yr of research involving 
organ preservation, surgical technique, and 
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the physiologic interrelationship of the liver 
with the pancreas and other intra~abdominal 
viscera. There were no means of preventing 
rejection at the beginning, but finally, the 
decision to go forward hinged on a strategy 
of immunosuppression developed in 1962 
that ultimately revolutionised trans-
plantation of all organs. 
The genesis of the idea 
Engraftrnent of an extra liver 
The first recorded mention of liver trans~ 
plantation in either scientific or lay 
literature was in 1955, when C. Stuart 
Welch (Albany, NY) described the trans-
plantation of an auxiliary liver to the right 
paravertebral gutter of mongrel dogs (2). It 
was then thought that the volume rather 
then the source of blood delivered to the 
liver through its double blood supply was the 
critical determinant of normal hepatic 
homeostasis. Welch provided his allografts 
with a portal venous inflow of fe-directed 
host inferior vena caval blood. When they 
rapidly atrophied, he incorrectly ascribed 
this to rejection only. 
The relevance of hepatotrophic factors 
Between 1956-58, at the University of 
Miami where I was a surgical resident, I 
developed non-transplant dog models to test 
the hypothesis that the liver and the 
pancreas cross-modulated. The first evidence 
suggesting that this was true came from 
studying the effect on insulin/carbohydrate 
metabolism of altering portal venous inflow 
with classical Eck or reverse Eck fistula in 
alloxan diabetic dogs (3). One of the other 
procedures developed for the investigation 
was total hepatectomy (4), the first stage of 
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orthotopic liver transplantation. 
Circumstances in Miami precluded further 
development (5). However, I performed 
orthotopic liver transplantation following 
host hepatectomy a few days after I moved 
to the Northwestern University (Chicago) 
in late June 1958, and repeated the ope-
ration once or twice/wk throughout the rest 
of the summer. I wondered if the poor 
performance of abnormally vascularised 
orthotopic livers (6) and the acute atrophy 
of Welch's auxiliary grafts could be 
explained by the transplants' lack of access 
to an unknown factor (suspected to he 
insulin) present in high concentration in 
portal venous blood (7): 
Proving the insulin hypothesis and 
convincing sceptics that insulin was a true 
hepatic growth factor, required nearly 15yr 
(8, 9). In the end however, a precise 
explanation could be provided for the 
previously enigmatic pathophysiology of 
Eck's fistula (10). Eventually, the identi-
fication of a family of factors with insulin-
like hepatotrophic properties which 
controlled liver structure, function, and the 
capacity for regeneration defined the new 
field of hepatotrophic physiology (Table 1, 
9-20). 
Orthotopic liver transplantation 
In 1956, Jack Cannon of the University of 
California, Los Angeles was the first to 
report liver replacement, citing Welch's 
article as the stimulus for his work. Cannon 
alluded to "several successful operations" 
"without survival of the patient" [dogs] but 
with no details (21). Definitive information 
came from the canine experiments at 
Northwestern University (6, 22) and 
independently from the team of Francis D. 
Moore at the Peter Bent Brigham Hospital 
("The Brigham", Boston) (23, 24). In 
contrast to the metaholic basis of the 
Chicago initiative, Moore's liver research 
was an offshoot of an institutional 
commitment to kidney transplantation that 
had begun a decade earlier. 
Because effective immune suppression was 
not yet available in either lahoratory, it was 
only possihle to do little more than develup 
the operation and study the events of 
unaltered rejection. Between 1958 and early 
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Table 1. Growth factors revealed by studies in eck fistula 
models (1994) 
Stimulatory 
Hormones: 
Insulin 
Growth factors: 
Cytosol substrate and ALR 
IGF II 
TGF-a.6. 
HGF 
Immunosuppressants: 
Cyclosporine 
FK506 
Immunophilins 
FK13PI2 
Inhibitory 
Growth factors: 
9,10 
11,12,13,14 
15 
15 
15 
16 
17 
18 
qdc~· 19 
Immunosuppression: 
Rapamycin 20 
.6. Mitogenic in t/\\u<.' culture; • inhibitory in tisme wlture 
1960, 31 of these orthotopic procedures in 
dogs were performed in Boston and 80 in 
Chicago. All animals with ;?:4dy survival had 
histopathologic evidence of allograft 
rejection. The technical principles that 
emerged from this collective experience 
were: 
i. the need for splanchnic venous blood for 
optimal portal re-vascularisation (6); 
ii. core-cooling of the allograft hy infusion 
of chilled solutions into the portal vein 
(6) as is practised clinically today, and 
iii. decompression of the occluded 
splanchnic and systemic venous pools 
into the upper vena caval system through 
external venous bypasses during the 
anhepatic stage (6, 24). 
In addition to liver transplantation alone, 
modifications had been added by the end of 
1959, including the multivisceral en-
graftment procedures (25, 26) that would be 
used clinically with essentially no change 3 
decades later (27). 
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Movement to the clinic 
The advent of immunosuppression 
Total body irradiation (TBI) (28), adrenal 
cortical steroids (29), and the myelotoxic 
drug 6-mercaptopurine (6-MP) (30,31) 
were shown to mudestly prolong skin 
allograft survival in several animal species, 
between 1953-1959. Using TBI, successful 
kidney transplantation from fraternal 
(dizygotic) twin donors was accomplished in 
pts at the Brigham in January, 1959 and 
again 5mo later in Paris. Although the 
genetic barrier to transplantation had finally 
been breached in humans, liver transplant 
operations still had no conceivable 
application. Pre-operative conditioning of 
hepatic canine recipients with TBI appeared 
to preclude even peri-operative, much less 
extended, survival (32). 
The pre-clinical kidney transplant studies of 
6-mercaptopurine (6-MP) and its analogue, 
azathioprine, by the Englishman, Roy CaIne 
(33, 34) with Joseph Murray at the Brigham 
(J5, 36) and by Zukoski, Lee and Hume in 
Richmond (37) were viewed in a different 
light. Whereas kidney transplantation with 
long survival had never been possible in 
mongrel dogs previously, about 5\Yo of 
animals given one or the other of the new 
drugs lived >100d. The objective of 
exploiting hepatic replacement to treat 
human liver disease was settled upon as a 
high priority during discussions in June, 
1961, with William R. Waddell, who left the 
Massachusetts General Hospital to assume 
the chairmanship of surgery at the 
University of Colorado Smo before I joined 
him from Chicago. This would r~quire 
establishing a track record in renal trans-
plantation, a procedure under formal clinical 
development in the United States only at 
the Brigham (Joseph Murray), the Medical 
College of Virginia (David Hume), and the 
University of California, Los Angeles 
(UCLA) where Willard Goodwin had put 
his program on hold. 
Our clinical plans for both organs were 
shelved in January 1962. We had been 
following the tracks laid by the American 
kidney transplant pioneers and those in Paris 
(Rene Kuss and Jean Hamburger), only to 
realise eventually that we had joined them 
, FORUM 7.1 (supp\. 6) 1997 21 
in a therapeutic cuI-dc-sac. As late as March 
I, 1963, the date of our first liver trans-
plantation, only 6 recipients of kidney 
allografts in the world had survived::: 1 yr 
(one in Boston and 5 in Paris), all treated 
with TBI. The clinical results with 
azathioprine-based immunosuppression were 
little better (38, 39). Although the longest 
surviving kidney recipient treated solely 
with azathioprine or 6-MP based therapy 
from April 1960 to April 1962, was now 
11 mo post-operative, we knew from contact 
with Murray that the patient had dete-
riorating renal function. 
An empirical treatment strategy 
The experimental results in the Denver VA 
canine laboratory resembled those in Boston 
and Richmond until the summer of 1962 
when a significant reproducible observation 
was mad e (40, 41) . Delayed high doses of 
prednisone were shown to reliably reverse 
kidney (and, in pilot studies, liver) rejection 
that usually developed under primary 
azathinprine therapy. Most of the dogs died 
of complications of steroid-induced peptic 
ulceration, but several lived for years after 
discontinuation of prednisone and even 
when azathioprine was also stopped. Using 
the "double-drug cocktail", the Colorado 
clinical kidney transplant program was 
finally opened in November, 1962. 
The first 10 cases were compiled rapidly and 
reported in the October 1963 issue of 
Surgery, Gynecology, and Ohstetrics (42), 
preceding the article on liver transplantation 
in the same journal by 2mo (1). Four ofthe 
10 renal recipients survived :::25yr including 
2 who still bear the longest continuously-
functioning kidney allografts in the world 
after a third of a century (43). I t was obvious 
that these pts could return to an unrestricted 
environment on reduced-maintenance 
immunosuppression, suggesting that a state 
of relative host/graft non-reactivity had been 
accidentally but regularly induced by the 
renal allografts. The controversial, but as it 
d . "I " ( turne· out apPOSite, term to erance see 
later) was used to describe the change. This 
was the signal that triggered the liver trials. 
The first 3 pts entered were: a moribund 
child with biliary atresia, a 48yr-old man 
with Laennec's cirrhosis and an unresectable 
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hepatoma, and a 62yr-old man with a 
completely obstructing bile duct carcinoma 
who had previously undergone bilateral 
above-knee amputations for peripheral 
vascular disease. Their high risk factors 
would preclude candidacy today. Although 2 
survived the operation, none of them left 
the hospital alive. 
The aftermath 
The Colorado kidney center "mushroomed" 
overnight while the spark that had ignited 
it, liver transplantation, was consigned to a 
self-imposed 3.5yr worldwide moratorium by 
the end of 1963, following 4 more failures: 2 
in Denver (7) and one each in Boston (44) 
and Paris (45). Three advances applicable to 
all organs were made during this period: 
i. the purification and clinical introduction 
in 1966 of antilymphocyte globulin 
(ALG) for use with azathioprine and 
prednisone in a triple-drug regimen (46); 
11. preservation techniques that allowed 
livers to be stored ex vivo for one to 2d 
(47); and; 
iii. the demonstration (with Paul Terasaki of 
UCLA) that the quality of donor/ 
recipient HLA-matching had little 
association with kidney transplant 
outcome (48). When the liver program 
was reopened in July, 1967, during the 
2yr fellowship of Carl Grnth 
(Stockholm), multiple examples of pro-
longed liver recipient survival were 
produced (49,50). 
A second liver transplant program was 
founded in 1968 by Roy Caine of Cambridge 
University and fostered by a long lasting 
inter-university collaboration with the 
hepatologist Roger Williams at King's 
College Hospital, London. The American 
and English teams sustained each other for 
the next dozen years, joined in the early 
1970's by Rudolph Pichlmayr in Hannover 
and by Henri Bismuth in Paris, always 
tantalisingly close to making liver trans-
plantation, a service. In Denver, 170 pts 
underwent the operation between 1963 and 
1979. Although only 56 survived for 1 yr, 25 
were alive after 13 to 22yr at the end of 1992 
(51), and 19 remain alive today with follow-
ups of 17 to 27 years. The immuno-
- -
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suppressive regimens used in this period and 
subsequently are summarised in Table 2 (38, 
42, 46, 52-61). 
Although the feasibility of liver trans-
plantation was established, the results 
remained unacceptable until Sir Roy CaIne 
introduced cyclosporine in a clinical series 
that included 2 liver recipients (58). In a 
return to the past, the full potential of the 
new drug was realised for transplantation of 
the kidney (59), liver (60), and eventually 
all organs when it was combined with 
prednisone or used in triple-drug cocktails. 
The stampede to develop extra-renal 
transplant centres began. Nine years later, 
expectations moved up another notch with 
the substitution of tacrolimus for cyclo-
sporine (61) (Table 2). 
In retrospect 
Most failed trials are doomed to be 
footnotes, if as much, in the pages of history. 
The 1963 liver transplant article escaped 
obscurity because it was based on principles 
which were enduring. Aside from the 
manifold details of the difficult operation, 
including the role of and complications from 
veno-venous bypass, there was already 
accurate insight into the importance of 
hepatotrophic physiology, and into the cause 
and treatment of metabolic acidosis. The 
only non-surgeon author, Kurt von Kaulla, 
anticipated the intra-operative coagulation 
disorders, monitored them with serial 
thromboelastograms, and provided 
treatment with blood components and 
epsilon amino caproic acid (an analogue of 
the currently used aprotinine). Lessons from 
the research preceding the clinical trial had 
already cross-fertilised to the kidney and 
were eventually exploited for all kinds of 
allografts: core-cooling by infusion of chilled 
intravascular fluids, in situ procurement 
procedures that presaged the standard 
flexible procedures of today (62), and the 
intravascular techniques required for close-
quarter anastomoses. 
However, none of the generically applicable 
advances, or all together, remotely 
approached in importance the realisation in 
the summer of 1962 that rejection could be 
engineered into prolonged allograft and 
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Table 2. Principal immunosuppressive drug regimens and adjunts4. used clinically 
I veardepCribe~fa~dl· .' " .. i"" K~[: ...••• ;fF~IK~giK;; ",_ .. 03 r.ii·Usedfor 01 Agents Place reporte-!Eret~ ...... ·ii.; : .·i il;l.. .'C....; •.• ; ollgans 
Total hody 1960 (52) BostLln Ineffective, No 
irradiation dangerous 
Azathioprine 1962 (38) Boston Ineffective, No 
dangerous 
Azathioprine- 1963 (42) Denver Suboptimal Yes, liver 
steroids 
Thoracic duct 1963 (53) Stockholm Nuisance: Yes·, liver 
drainage as requires 
adjunct 20 to 30 days 
pretreatment 
Thymectomy 1963 (54) Denver Unproven value Yes, rarely 
as adjunct in 1963 
Splenectomy as 1963 (54) Denver No longer Yes, once 
adjunct necessary commonly 
for liver 
ALG as adjunct 1966 (46) Denver Suboptimal Yes 
CY substitute for 1970 (55) Denver No advantage, Yes"', liver 
azathioprine except for 
patients with 
azathioprinc toxicity 
Total lymphoid 1979 (56, 57) Palo Alto, Dangcrous, extensive Yes·, for 
liver 
irradiation Minneapolis preparation, not 
quickly reversible 
Cyclosporinc 1978-1979 (58) Cambridge Suboptimal Yes 
Cyclnsporine- 1980(59,60) Denvcr Nephrotoxicity, Yes 
steroids rejection not 
always controlled 
FKSOo-steroids 1989 (61) Pittsburgh Nephrotoxicity, Yes 
rejection not 
always controlled 
4. Until 1966. these were developed with kidney transplantation and applied for livers. From 1966 onward, the liver increasingly 
became the dominant test orgnll. 
• It was nor realised until much later that pre-treatment for 3 to 4 wk before transplantation was a necessary condition for effective use 
(JfTDD. 
'" These trials tt'ere summarised many years later with at least 1 Oyr follou'-up for surviving !Jts. 
• By Professor l.A Myburgh of lohannesburs; 
reClplent survival by the strategic use of 
existing agents. The cyclic pattern of conva-
lescence and the consequent achievement of 
23 
allograft acceptance remained enigmatic 
until it was discovered in 1992 that long-
surviving organ recipients had donor 
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leucocyte chimerism in their blood, skin, 
lymph nodes, and other sites as distant as 3 
decades post-transplantation (51, 63). 
Then, it could be seen that the prototypic 
post-operative events following trans-
plantation of all organs were the product of a 
double immune reaction; host-versus-graft 
(rejection) and graft-versus-hosr. Potentially 
tolerant "passenger leucocytes" uf BM origin 
including pluripotent stem cells had 
migrated from organs and engrafted 
peripherally. This was the seminal me-
chanism of organ allograft acceptance which 
opened the door to the future. The epiphany 
(64) provided the missing link to the 
demonstration 40yr earlier by Billingham, 
Brent, Medawar (65) that it was possible to 
induce acquired immunologic tolerance. 
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